

## Formulary Adherence Checklist for NICE Technology Appraisals About Medicines



Developed for the NHS by: **East and South East England Specialist Pharmacy Services**

**Milton Keynes Health Economy**

This spreadsheet is updated monthly and enables self-audit of a medicines formulary for adherence to current NICE Technology Appraisals. **Version 17. May 2017**  
 All guidelines refer to adults unless indicated. No copyright is asserted on this material if used for non-commercial purposes within the NHS.

Technology appraisal (TA) Titles are hyperlinks to full guidance	Date of TA Release	Availability of medicine for NHS patients with this medical condition, as indicated by NICE	Adherence of local formulary to NICE				
			Yes (mark 'x' if applicable)	N/A (mark 'x' if applicable)	Date of local decision (DD/MM/YY)	Time to implement (days)	Notes (e.g. rationale, method of making available)
<b>2016/2017</b>							
<a href="#">Cetuximab and panitumumab for previously untreated metastatic colorectal cancer (TA439)</a>	29/03/2017	<b>Cetuximab</b> is recommended, within its marketing authorisation, as an option for previously untreated epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer in adults	x		24/05/2017	56	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal) (TA438)</a>	29/03/2017	<b>Alectinib</b> - unable to make a recommendation about the use in the NHS of alectinib for anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer previously treated with crizotinib because no evidence submission was received from Roche	x		24/04/2017	26	Terminated Appraisal by NICE
<a href="#">Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal) (TA437)</a>	22/03/2017	<b>Ibrutinib with bendamustine and rituximab</b> - unable to make a recommendation about the use in the NHS of ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy because no evidence submission was received from Janssen-Cilag	x		24/04/2017	33	Terminated Appraisal by NICE
<a href="#">Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal) (TA436)</a>	22/03/2017	<b>Bevacizumab</b> - was unable to make a recommendation about the use in the NHS of bevacizumab for treating epidermal growth factor receptor mutation-positive non-small-cell lung cancer because no evidence submission was received from Roche	x		24/04/2017	33	Terminated Appraisal by NICE
<a href="#">Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal) (TA435)</a>	22/03/2017	<b>Tenofovir alafenamide</b> - unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was received from Gilead	x		24/04/2017	33	Terminated Appraisal by NICE
<a href="#">Elotuzumab for previously treated multiple myeloma (terminated appraisal) (TA434)</a>	22/03/2017	<b>Elotuzumab</b> - unable to make a recommendation about the use in the NHS of because no evidence submission was received from Bristol-Myers Squibb.	x		24/04/2017	33	Terminated Appraisal by NICE

<a href="#">Apremilast for treating active psoriatic arthritis (TA433)</a>	22/02/2017	<b>Apremilast</b> , alone or in combination with disease-modifying antirheumatic drugs (DMARDs), is recommended as an option for treating active psoriatic arthritis in adults	x		22/03/2017	28	CCG commissioned. Patient access scheme applies. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements and CCG agreed criteria
<a href="#">Everolimus for advanced renal cell carcinoma after previous treatment (TA432)</a>	22/02/2017	<b>Everolimus</b> is recommended within its marketing authorisation as an option for treating advanced renal cell carcinoma that has progressed during or after treatment with vascular endothelial growth factor targeted therapy, only if the company provides it with the discount agreed in the patient access scheme.	x		22/03/2017	28	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Mepolizumab for treating severe refractory eosinophilic asthma (TA431)</a>	25/01/2017	<b>Mepolizumab</b> , as an add-on to optimised standard therapy, is recommended as an option for treating severe refractory eosinophilic asthma in adults within set criteria.	x		22/03/2017	56	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)</a>	25/01/2017	<b>Sofosbuvir–velpatasvir</b> is recommended as an option for treating chronic hepatitis C in adults, only if the company provides the drug with the discount agreed in the simple discount agreement.	x		22/03/2017	56	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)</a>	25/01/2017	<b>Ibrutinib</b> alone is recommended within its marketing authorisation as an option for treating chronic lymphocytic leukaemia in adults	x		22/03/2017	56	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy (TA428)</a>	11/01/2017	<b>Pembrolizumab</b> is recommended as an option for treating locally advanced or metastatic PD-L1-positive non-small-cell lung cancer in adults who have had at least one chemotherapy (and targeted treatment if they have an epidermal growth factor receptor [EGFR]- or anaplastic lymphoma kinase [ALK]-positive tumour)	x		01/02/2017	21	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements

<a href="#">Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib (TA427)</a>	11/01/2017	<b>Pomalidomide</b> , in combination with low-dose dexamethasone, is recommended as an option for treating multiple myeloma in adults at third or subsequent relapse; that is, after 3 previous treatments including both lenalidomide and bortezomib, only when the company provides pomalidomide with the discount agreed in the patient access scheme.	x		01/02/2017	21	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia (TA426)</a>	21/12/2016	<b>Imatinib</b> is recommended as an option for untreated, chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults.  <b>Dasatinib</b> and <b>nilotinib</b> are recommended, within their marketing authorisations, as options for untreated chronic-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults.	x		01/02/2017	42	NHSE commissioned. Patient access scheme applies. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia (TA425)</a>	21/12/2016	<b>Dasatinib</b> and <b>nilotinib</b> are recommended as options for treating only chronic- or accelerated-phase Philadelphia-chromosome-positive chronic myeloid leukaemia in adults, if: •they cannot have imatinib, or their disease is imatinib-resistant and •the companies provide the drugs with the discounts agreed in the relevant patient access schemes.  <b>High-dose imatinib</b> (that is, 600mg in the chronic phase or 800mg in the accelerated and blast-crisis phases) is not recommended for treating Philadelphia-chromosome-positive chronic myeloid leukaemia in adults whose disease is imatinib-resistant.	x		01/02/2017	42	NHSE commissioned. Patient access scheme applies. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer (TA424)</a>	21/12/2016	<b>Pertuzumab</b> , in combination with trastuzumab and chemotherapy, is recommended, within its marketing authorisation, as an option for the neoadjuvant treatment of adults with HER2-positive breast cancer, locally advanced, inflammatory or early-stage breast cancer at high risk of recurrence.	x		01/02/2017	42	NHSE commissioned. Patient access scheme applies.  Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
<a href="#">Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (TA423)</a>	21/12/2016	<b>Eribulin</b> is recommended as an option for treating locally advanced or metastatic breast cancer in adults, only when: •it has progressed after at least 2 chemotherapy regimens (which may include an anthracycline or a taxane, and capecitabine) • Patient access scheme applies.	x		01/02/2017		NHSE commissioned. Patient access scheme applies.  Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.

<a href="#">Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA422)</a>	21/12/2016	<b>Crizotinib</b> is recommended, within its marketing authorisation, as an option for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.	x		01/02/2017	42	NHSE commissioned. Patient access scheme applies.
<a href="#">Everolimus with exemestane for treating advanced breast cancer after endocrine therapy (TA421)</a>	21/12/2016	<b>Everolimus</b> , in combination with exemestane, is recommended within its marketing authorisation, as an option for treating advanced human epidermal growth factor receptor 2 (HER2)-negative, hormone-receptor-positive breast cancer in postmenopausal women without symptomatic visceral disease that has recurred or progressed after a non-steroidal aromatase inhibitor.	x		01/02/2017	42	NHSE commissioned. Patient access scheme applies.  Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
<a href="#">Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)</a>	14/12/2016	<b>Ticagrelor</b> , in combination with aspirin, is recommended within its marketing authorisation as an option for preventing atherothrombotic events in adults who had a myocardial infarction and who are at high risk of a further event.	x		01/02/2017	49	CCG commissioned. Treatment should be stopped when clinically indicated or at a maximum of 3 years.
<a href="#">Apremilast for treating moderate to severe plaque psoriasis (TA419)</a>	23/11/2016	<b>Apremilast</b> is recommended as an option for treating chronic plaque psoriasis in adults whose disease has not responded to other systemic therapies, including ciclosporin, methotrexate and PUVA (psoralen and ultraviolet-A light), or when these treatments are contraindicated or not tolerated	x		01/02/2017	70	CCG commissioned. Patient access scheme applies.  Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements.
<a href="#">Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)</a>	23/11/2016	<b>Dapagliflozin</b> in a triple therapy regimen is recommended as an option for treating type 2 diabetes in adults, only in combination with metformin and a sulfonylurea.	x		01/02/2017	70	CCG commissioned. No significant resource impact anticipated, this is because the technology is an option alongside current standard treatment options and the drugs are similarly priced.
<a href="#">Nivolumab for previously treated advanced renal cell carcinoma (TA417)</a>	23/11/2016	<b>Nivolumab</b> is recommended, within its marketing authorisation, as an option for previously treated advanced renal cell carcinoma in adults, when the company provides nivolumab with the discount agreed in the patient access scheme	x		01/02/2017	70	CCG commissioned. Patient access scheme applies.
<a href="#">Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer [TA416]</a>	26/10/2016	<b>Osimertinib</b> is recommended as an option for use within the Cancer Drugs Fund for treating locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer in adults whose disease has progressed	x		30/11/2016	35	NHSE commissioned  The resource impact of osimertinib will be covered by the Cancer Drugs Fund budget. The guidance will be reviewed by the date that the managed access agreement expires (March 2019) or when the results of the data collection as part of the managed access agreement are available, whichever is sooner. The aim of the CDF guidance review is to decide whether or not the drug can be recommended for routine use.  Approved for addition to the formulary. Link the NICE TA commissioning statements.

<a href="#">Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor [TA415]</a>	26/10/2016	<b>Certolizumab pegol</b> , in combination with methotrexate, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other disease-modifying antirheumatic drugs (DMARDs) including at least 1 tumour necrosis factor-alpha (TNF-alpha) inhibitor. <b>Certolizumab pegol</b> , as monotherapy, is recommended as an option for treating active rheumatoid arthritis in adults whose disease has responded inadequately to, or who cannot tolerate, other DMARDs including at least 1 TNF-alpha inhibitor.	x		30/11/2016	35	CCG commissioned. No significant cost impact anticipated because the technology is an option alongside current standard treatment options. The Department of Health and the company have agreed a patient access scheme, and the cost of treatment is anticipated to be similar to existing drugs.  Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [TA414]</a>	26/10/2016	<b>Cobimetinib</b> in combination with vemurafenib is not recommended within its marketing authorisation for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation			30/11/2016	35	<b>Not recommended</b>
<a href="#">Elbasvir-grazoprevir for treating chronic hepatitis C [TA413]</a>	26/10/2016	<b>Elbasvir-grazoprevir</b> is recommended, within its marketing authorisation, as an option for treating genotype 1 or 4 chronic hepatitis C in adults, as specified in the table in the guidance	x		30/11/2016	35	NHSE commissioned. Approved for addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases [TA412]</a>	28/09/2016	<b>Radium-223 dichloride</b> is recommended as an option for treating hormone-relapsed prostate cancer, symptomatic bone metastases and no known visceral metastases in adults		x	30/11/2016	63	Not applicable
<a href="#">Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer [TA411]</a>	28/09/2016	<b>Necitumumab</b> , in combination with gemcitabine and cisplatin, is <u>not</u> recommended for adults with locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy	x		30/11/2016	63	<b>Not recommended</b>
<a href="#">Talimogene laherparepvec for treating unresectable metastatic melanoma [TA410]</a>	28/09/2016	<b>Talimogene laherparepvec</b> is recommended, in adults, as an option for treating unresectable, regionally or distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone, brain, lung or other internal organs	x		30/11/2016	63	NHSE commissioned. Patient Access Scheme applies. Only if treatment with systemically administered immunotherapies is not suitable
<a href="#">Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion [TA409]</a>	28/09/2016	Aflibercept is recommended as an option within its marketing authorisation for treating visual impairment in adults caused by macular oedema after branch retinal vein occlusion	x		30/11/2016	63	CCG commissioned. Patient Access Scheme applies.
<a href="#">Pegaspargase for treating acute lymphoblastic leukaemia [TA408]</a>	28/09/2016	<b>Pegaspargase</b> , as part of antineoplastic combination therapy, is recommended as an option for treating acute lymphoblastic leukaemia in children, young people and adults	x		30/11/2016	63	NHSE commissioned. Only when they have untreated newly diagnosed disease.

<a href="#">Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors [TA407]</a>	28/09/2016	<b>Secukinumab</b> is recommended as an option for treating active ankylosing spondylitis in adults whose disease has responded inadequately to conventional therapy (non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors)	x		30/11/2016	63	CCG commissioned. Patient Access Scheme applies.
<a href="#">Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer [TA406]</a>	28/09/2016	<b>Crizotinib</b> is recommended as an option for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer in adults.	x		30/11/2016	63	NHSE commissioned. Patient Access Scheme applies.
<a href="#">Trifluridine–tipiracil for previously treated metastatic colorectal cancer [TA405]</a>	24/08/2016	<b>Trifluridine–tipiracil</b> is recommended as an option for treating metastatic colorectal cancer	x		28/09/2016	35	Approved for the addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Degarelix for treating advanced hormone-dependent prostate cancer [TA404]</a>	24/08/2016	<b>Degarelix</b> is recommended as an option for treating advanced hormone-dependent prostate cancer in people with spinal metastases	x		28/09/2016	35	Approved for the addition to the formulary and to be used in line with NICE guidance and commissioning statements and develop a compliance form
<a href="#">Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer [TA403]</a>	24/08/2016	<b>Ramucirumab</b> , in combination with docetaxel, is not recommended for treating locally advanced or metastatic non-small-cell lung cancer in adults whose disease has progressed after platinum-based chemotherapy	x		28/09/2016	35	<b>Not recommended</b>
<a href="#">Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin [TA402]</a>	24/08/2016	<b>Pemetrexed</b> is recommended as an option for the maintenance treatment of locally advanced or metastatic non-squamous non-small-cell lung cancer in adults.	x		28/09/2016	35	Approved for the addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Bosutinib for previously treated chronic myeloid leukaemia [TA401]</a>	24/08/2016	<b>Bosutinib</b> is recommended as an option for chronic, accelerated and blast phase Philadelphia chromosome positive chronic myeloid leukaemia in adults	x		28/09/2016	35	Approved for the addition to the formulary and to be used in line with NICE guidance and commissioning statements
<a href="#">Nivolumab in combination with ipilimumab for treating advanced melanoma [TA400]</a>	27/07/2016	<b>Nivolumab in combination with ipilimumab</b> is recommended as an option for treating advanced (unresectable or metastatic) melanoma.	x		28/09/2016	63	Only when the company provides ipilimumab with the discount agreed in the PAS. Agreed to add Nivolumab Injection and the NICE link to the formulary
<a href="#">Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts [TA399]</a>	27/07/2016	<b>Azacitidine</b> is not recommended for treating acute myeloid leukaemia with more than 30% bone marrow blasts in people of 65 years or older who are not eligible for haematopoietic stem cell transplant.	x		28/09/2016	63	<b>Not recommended</b>
<a href="#">Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation [TA398]</a>	27/07/2016	<b>Lumacaftor–ivacaftor</b> is not recommended for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	x		28/09/2016	63	<b>Not recommended</b>
<a href="#">Belimumab for treating active autoantibody-positive systemic lupus erythematosus [TA397]</a>	22/06/2016	<b>Belimumab</b> is recommended as an option as add-on treatment for active autoantibody-positive systemic lupus erythematosus in adults	x		30/07/2016	38	NHSE. Patient Access Scheme applies

<a href="#">Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma [TA396]</a>	22/06/2016	<b>Trametinib</b> in combination with <b>dabrafenib</b> is recommended as an option for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation	x		30/07/2016	38	NHSE. Patient Access Scheme applies
<a href="#">Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer [TA395]</a>	22/06/2016	<b>Ceritinib</b> is recommended as an option for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have previously had crizotinib.	x		30/07/2016	38	NHSE. Patient Access Scheme applies
<a href="#">Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia [TA394]</a>	22/06/2016	<b>Evolocumab</b> is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia.	x		30/07/2016	38	CCG. Patient Access Scheme applies. Approved for the addition to the formulary and to be used only in accordance to an agreed pathway.
<a href="#">Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia [TA393]</a>	22/06/2016	<b>Alirocumab</b> is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia.	x		30/07/2016	38	CCG. Patient Access Scheme applies. Approved for the addition to the formulary and to be used only in accordance to an agreed pathway.
<a href="#">Adalimumab for treating moderate to severe hidradenitis suppurativa [TA392]</a>	22/06/2016	<b>Adalimumab</b> is recommended as an option for treating active moderate to severe hidradenitis suppurativa in adults whose disease has not responded to conventional systemic therapy.	x		30/07/2016	38	CCG. Patient Access Scheme applies.
<a href="#">Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel [TA391]</a>	25/05/2016	<b>Cabazitaxel</b> in combination with prednisone or prednisolone is recommended as an option for treating metastatic hormone-relapsed prostate cancer in people whose disease has progressed during or after docetaxel chemotherapy.	x		30/07/2016	66	NHSE
<a href="#">Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes [TA390]</a>	25/05/2016	<b>Canagliflozin, dapagliflozin and empagliflozin</b> as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control.	x		30/07/2016	66	CCG. Only if: <ul style="list-style-type: none"> <li>• a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and</li> <li>• a sulfonylurea or pioglitazone is not appropriate.</li> </ul>
<a href="#">Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer [TA389]</a>	26/04/2016	<b>Paclitaxel</b> as monotherapy or in combination with platinum, and <b>pegylated liposomal doxorubicin hydrochloride (PLDH)</b> as monotherapy or in combination with platinum, are recommended as options for treating recurrent ovarian cancer. <b>Trabectedin</b> in combination with PLDH, <b>gemcitabine</b> in combination with carboplatin, and <b>topotecan</b> are not recommended for treating the first recurrence of platinum-sensitive ovarian cancer. <b>Topotecan</b> is also not recommended for treating recurrent platinum-resistant or platinum-refractory ovarian cancer	x		25/05/2016	29	NHSE commissioned. Prescribing to follow east midlands cancer network protocols
<a href="#">Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction [TA388]</a>	27/04/2016	<b>Sacubitril valsartan</b> is recommended as an option for treating symptomatic chronic heart failure with reduced ejection fraction.	x		25/05/2016	28	Early Access to Medicines Scheme recommended but not a legal requirement. To follow agreed pathway.

<a href="#">Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated [TA387]</a>	26/04/2016	<b>Abiraterone</b> in combination with prednisone or prednisolone is recommended as an option for treating metastatic hormone-relapsed prostate cancer.	x		25/05/2016	29	NHSE commissioned. Prescribing to follow east midlands cancer network protocols Add to the formulary (RED)
			53	1			
			% "Yes"	% "N/A"	-	Average implement time (days)	
<b>Adherence statistics for 2016-17</b>			100%	1%		45	